Transvaginal ultrasound is better at identifying cases of deep retrocervical and rectosigmoid endometriosis than MRI and clinical examination. It has better sensitivity, specificity, positive predictive value, negative predictive value, and accuracy, according to a recent study in Brazil.
Transvaginal ultrasound is better at identifying cases of deep retrocervical and rectosigmoid endometriosis than MRI and clinical examination. It has better sensitivity, specificity, positive predictive value, negative predictive value, and accuracy, according to a recent study in Brazil.
Dr. Mauricio S. Abrao and colleagues at the department of obstetrics and gynecology in São Paulo University published their study in the Oct. 18 issue of Human Reproduction. They studied 104 patients with clinically suspected endometriosis.
Each patient received a clinical examination, pelvic MRI, and transvaginal ultrasound previous to video laparoscopic surgery. The findings from these exams were then matched with histopathological confirmation of endometriosis.
Of the 104 patients, 98 (94.2%) received a confirmed histopathalogical diagnosis of endometriosis. The researchers were focused on rectosigmoid and retrocervical endometriosis, some of the most severe forms of deep pelvic endometriosis requiring more extensive surgical treatment.
They found that standard digital vaginal examination had a sensitivity of 72%, specificity of 54%, positive predictive value of 63%, negative predictive value of 64%, and accuracy of 63% for detecting rectosigmoid endometriosis. For retrocervical endometriosis, digital vaginal examination had a sensitivity of 68%, specificity of 46%, positive predictive value of 45%, negative predictive value of 69%, and accuracy of 55%.
Pelvic MRI performed better for rectosigmoid endometriosis, with a sensitivity of 83%, specificity of 98%, positive predictive value of 98%, negative predictive value of 85%, and accuracy of 90%. For retrocervical endometriosis, pelvic MRI had a sensitivity of 76%, specificity of 68%, positive predictive value of 61%, negative predictive value of 81%, and accuracy of 71%.
But transvaginal ultrasound performed the best for rectosigmoid endometriosis, with a sensitivity of 98%, specificity of 100%, positive predictive value of 100%, negative predictive value of 98%, and accuracy of 99%. For retrocervical endometriosis, transvaginal ultrasound had a sensitivity of 95%, specificity of 98%, positive predictive value of 98%, negative predictive value of 97%, and accuracy of 97%.
The researchers concluded that transvaginal ultrasound is statistically superior to pelvic MRI and digital vaginal examination for assessing the extent of deep retrocervical and rectosigmoid endometriosis, confirming its important place in the preoperative planning of surgical strategies.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.